Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
Status:
Completed
Trial end date:
2019-02-09
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of sunitinib malate and how well it works in
treating patients with ovarian cancer that is persistent or has come back. Sunitinib malate
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and
by blocking blood flow to the tumor.